PHOXBIO announces new coronary pneumonia preventive nasal spray

-pHOXWELL significantly reduces the risk of high-risk healthcare workers contracting the new coronavirus by 63%, and its tolerance is comparable to placebo

-The new self-administered nasal spray is mainly used to increase the existing prevention and control measures of the new coronavirus (including personal protective equipment and vaccines)

-India initiates regulatory filings for new crown virus prevention claims

-The company is exploring strategic alternatives to promote products to the Indian and global markets to help fight the current new crown pneumonia epidemic and cope with the challenges of future disease outbreaks

London and New York, September 24, 2021/PRNewswire/ - pHOXBIO Ltd.

pHOXWELL is a self-administered preventive nasal spray.

Rakesh Uppal, chairman of the company, Professor of Cardiovascular Surgery at Queen Mary University of London and Director of Barts Life Sciences, said: "pHOXWELL is a major breakthrough

Research design and results

The study is a double-blind, randomized and placebo-controlled study, which aims to evaluate the efficacy and safety of pHOXWELL nasal spray in preventing high-risk professional healthcare workers in India from contracting the new coronavirus

The primary endpoint showed that the proportion of IgGS-positive subjects in the pHOXWELL group was 13.

The secondary endpoint of subjects with clinical symptoms also showed significant results in favor of pHOXWELL

The user acceptability endpoint was positive and remained positive throughout the study

A total of 648 subjects completed the study

The company is committed to benefiting society

pHOXBIO and its parent company, Raphael Labs, will currently initiate a regulatory filing based on clinical trial data to help relevant regulatory agencies respond to new coronavirus prevention claims

Professor Uppal said: “The losses caused by this epidemic to humans are heartbreaking.

pHOXWELL is low-cost, easy to produce, has long-term stability at room temperature, and can be shipped worldwide

About pHOXWELL

pHOXWELL is a combination of natural disinfectant and proprietary solution Vita Raphael, which can prevent viral infections

The protection time of pHOXWELL is 6-8 hours.

Airborne respiratory virus and the current gap

Viruses are one of the most contagious and debilitating airborne respiratory pathogens

Personal protective equipment is under-allocated or improperly used or prone to failure, and it is difficult to use in some areas

About About pHOXBIO and Raphael Labs

pHOXBIO is a private biopharmaceutical company, affiliated with Raphael Labs

Raphael Labs is a privately-owned biopharmaceutical company headquartered in Dublin.
Its business is mainly distributed in the United Kingdom.
It has many subsidiaries and is mainly dedicated to the development and commercialization of Raphael Labs’ proprietary formulation, Vita Raphael
.
Its subsidiaries include: pHOXBIO, which specializes in the treatment of respiratory diseases, pHOXMETICS, which specializes in cosmeceuticals, pHOXHEAL, which specializes in wound care, and a research and development department called pHOXWORX
.

The scientific leadership team of Raphael Labs includes Dame Kay Davies, Professor Emeritus of Oxford University and Doctor Lee Professor of Anatomy; Steve Davies, Waynflete Professor Emeritus of Chemistry, University of Oxford; Alan Dunton, MD, Boston; Goutham K Gorti, Member of the Royal College of Surgeons of New Jersey Mr.
; Áine McKnight, Professor of Viral Pathology, Blizard Institute, Queen Mary College, University of London; Angela Russell, Professor of Medicinal Chemistry, University of Oxford; Dr.
Jim Swales, Director of Clinical Trials, pHOXWELL; Mauro Teixeira, Professor of Immunology, Federal University of Minas Gerais; and London Rakesh Uppal, Professor of Cardiovascular Surgery at the William Harvey Institute at Queen Mary University, Barts Heart Centre and Director of Barts Life Sciences
.

Raphael Labs is supported by American Mark Timney, Graeme Bell and Michael Blash
.